Search | IOVS | ARVO Journals

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)

Scott Ellis; Anna Buchberger; Julie Holder; elise Orhan; Jane Hughes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2295. doi:

ARVO Annual Meeting Abstract June 2020

Proteomic analysis of vitreous humor samples obtained from donors with and without age-related macular degeneration (AMD) reveal an overactivation of complement protein expression.

Anna Buchberger; James Francis; Ashley Frazer-Abel; Selina McHarg; Paul N Bishop; Scott Ellis; Jane Hughes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3650. doi:

ARVO Annual Meeting Abstract June 2017

Evaluation of integrase-deficient vectors for lentiviral gene-transfer in corneal endothelium

Daniel Thieme; Scott Ellis; Thomas Armin Fuchsluger; Friedrich E Kruse

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4085. doi:

ARVO Annual Meeting Abstract September 2016

Phase I Safety and Tolerability results for RetinoStat ® , a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients with Advanced Neovascular Age-Related Macular Degeneration

Andreas K Lauer; Peter A Campochiaro; Elliott H Sohn; Michelle Kelleher; Richard Harrop; Julie Loader; Scott Ellis; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract June 2015

EncorStat ® : a human donor cornea genetically engineered to resist rejection in high risk patients

Scott Ellis; Maria Parker; Vicky Kennedy; Laura McCloskey; Trevor McFarland; Matt Hartzell; Binoy Appukuttan; Tim Stout; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2262. doi:

ARVO Annual Meeting Abstract June 2015

Results from the Phase I GEM study, evaluating safety and tolerability of subretinally-injected lentiviral vector (RetinoStat ® ) for the treatment of wet age-related macular degeneration (AMD)

Simon Chandler; Peter Campochiaro; Andreas Lauer; Elliott H Sohn; Tim Stout; Michelle Kelleher; Richard Harrop; Scott Ellis; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2284. doi:

ARVO Annual Meeting Abstract April 2014

NONCLINICAL DEVELOPMENT OF ENCORSTAT®, DONOR CORNEAL TISSUE GENETICALLY ENGINEERED TO PREVENT GRAFT REJECTION

Scott Ellis; Kyriacos Mitrophanous; Maria A Parker; Vicky Scripps; Trevor J McFarland; Matthew Hartzell; Binoy Appukuttan; Tim Stout

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3235. doi:

ARVO Annual Meeting Abstract April 2014

Lentiviral Gene therapies for wet AMD, Stargardt macula dystrophy and Usher Syndrome 1B : clinical trial updates

Madhu Davies; Scott Ellis; Nicola Adams; Katie Binley; Michelle Kelleher; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3299. doi:

ARVO Annual Meeting Abstract June 2013

Glaucoma-GT, a novel gene therapy treatment for primary open-angle glaucoma

Scott Ellis; Katie Binley; Vicky Scripps; Sharifah Iqball; Stuart Naylor; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2741. doi:

ARVO Annual Meeting Abstract June 2013

The LentiVector ® Gene Therapy Platform for Ocular Disease: a clinical update

Kyriacos Mitrophanous; Scott Ellis; James Miskin; Katie Binley; Michelle Kelleher; Cherry Lucas; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2744. doi:

ARVO Annual Meeting Abstract June 2013

Comparison of Neovascularization, Opacification and Cornea thickness in a Rabbit Model of Keratoplasty with Interrupted or Continuous Suture Techniques by Cornea fluorescein angiography and corneal OCT

Maria Parker; Trevor McFarland; Winston Chamberlain; Scott Ellis; Kyriacos Mitrophanous; Tim Stout

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3071. doi:

Retina June 2013

Transduction of Photoreceptors With Equine Infectious Anemia Virus Lentiviral Vectors: Safety and Biodistribution of StarGen for Stargardt Disease

PDF

Katie Binley; Peter Widdowson; Julie Loader; Michelle Kelleher; Sharifah Iqball; Georgina Ferrige; Jackie de Belin; Marie Carlucci; Diana Angell-Manning; Felicity Hurst; Scott Ellis; James Miskin; Alcides Fernandes; Paul Wong; Rando Allikmets; Christopher Bergstrom; Thomas Aaberg; Jiong Yan; Jian Kong; Peter Gouras; Annick Prefontaine; Mark Vezina; Martin Bussieres; Stuart Naylor; Kyriacos A. Mitrophanous
TAGS: disease vectors, equine infectious anemia virus, eye, gene transfer techniques, lentiviral vector, macaca, oryctolagus cuniculus, photoreceptors, safety, spatial vectors
Invest. Ophthalmol. Vis. Sci.. 2013; 54(6):4061-4071. doi: https://doi.org/10.1167/iovs.13-11871

ARVO Annual Meeting Abstract March 2012

LentiVector® Platform, a Highly Effective Equine Infectious Anaemia Virus-based Lentiviral Gene Therapy Platform for Ocular Disease

Scott Ellis; James Miskin; Katie Binley; Jackie de Belin; Julie Loader; Michelle Kelleher; Stuart Naylor; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1912. doi:

ARVO Annual Meeting Abstract March 2012

Evaluation Of EIAV Lentiviral Vectors In A Rabbit Model Of Corneal Rejection

Maria A. Parker; Trevor McFarland; Binoy Appukuttan; Matt Harzell; Kyriacos Mitrophanous; Tim Stout; Scott Ellis

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2397. doi:

ARVO Annual Meeting Abstract April 2011

Efficacy, Safety And Tolerability Of StargenTM, A Lentiviral-vector Based Gene Therapy For The Treatment Of Stargardt Disease, In Rabbits And Macaques

Peter Widdowson; Scott Ellis; Katie Binley; Martin Bussières; Annick Prefontaine; Mark Vezina; Rando Allikmets; Jian Kong; Kyriacos Mitrophanous; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):479. doi:

ARVO Annual Meeting Abstract April 2011

Biodistribution and Immunological Responses to the Lentiviral-Vector Based Gene Therapy Product RetinoStat® Following Subretinal Injection in Rabbits and Rhesus Macaques

Stuart M. Naylor; Michelle Kelleher; Julie Loader; Jackie de Belin; James Miskin; Georgina Ferrige; Marie Carlucci; Margaret Esapa; Scott Ellis; Peter Widdowson

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):484. doi:

ARVO Annual Meeting Abstract April 2011

Safety And Tolerability Of Retinostat®, A Lentiviral-vector Based Gene Therapy Product For The Treatment Of Wet Age-related Macular Degeneration, In Rabbits And Monkeys

Scott Ellis; Peter Widdowson; Katie Binley; T. Michael Nork; Paul Miller; Vlad Bantseev; Brian Christian; Kyriacos Mitrophanous; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):488. doi:

ARVO Annual Meeting Abstract April 2011

Subretinal Delivery Of Eiav-based Lentiviral Vectors In The Shaker1 Mouse Model For Usher Syndrometype 1b : Development Of Ushstat®

Marisa L. Zallocchi; Katie Binely; Yatish Lad; Scott Ellis; Peter Widdowson; Kyri Mitrophanous; You-Wei Peng; Linda Cheung; Dominic Cosgrove

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):489. doi:

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)

Proteomic analysis of vitreous humor samples obtained from donors with and without age-related macular degeneration (AMD) reveal an overactivation of complement protein expression.

Evaluation of integrase-deficient vectors for lentiviral gene-transfer in corneal endothelium

Phase I Safety and Tolerability results for RetinoStat ® , a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients with Advanced Neovascular Age-Related Macular Degeneration

EncorStat ® : a human donor cornea genetically engineered to resist rejection in high risk patients

Results from the Phase I GEM study, evaluating safety and tolerability of subretinally-injected lentiviral vector (RetinoStat ® ) for the treatment of wet age-related macular degeneration (AMD)

NONCLINICAL DEVELOPMENT OF ENCORSTAT®, DONOR CORNEAL TISSUE GENETICALLY ENGINEERED TO PREVENT GRAFT REJECTION

Lentiviral Gene therapies for wet AMD, Stargardt macula dystrophy and Usher Syndrome 1B : clinical trial updates

Glaucoma-GT, a novel gene therapy treatment for primary open-angle glaucoma

The LentiVector ® Gene Therapy Platform for Ocular Disease: a clinical update

Comparison of Neovascularization, Opacification and Cornea thickness in a Rabbit Model of Keratoplasty with Interrupted or Continuous Suture Techniques by Cornea fluorescein angiography and corneal OCT

Transduction of Photoreceptors With Equine Infectious Anemia Virus Lentiviral Vectors: Safety and Biodistribution of StarGen for Stargardt Disease

LentiVector® Platform, a Highly Effective Equine Infectious Anaemia Virus-based Lentiviral Gene Therapy Platform for Ocular Disease

Evaluation Of EIAV Lentiviral Vectors In A Rabbit Model Of Corneal Rejection

Efficacy, Safety And Tolerability Of StargenTM, A Lentiviral-vector Based Gene Therapy For The Treatment Of Stargardt Disease, In Rabbits And Macaques

Biodistribution and Immunological Responses to the Lentiviral-Vector Based Gene Therapy Product RetinoStat® Following Subretinal Injection in Rabbits and Rhesus Macaques

Safety And Tolerability Of Retinostat®, A Lentiviral-vector Based Gene Therapy Product For The Treatment Of Wet Age-related Macular Degeneration, In Rabbits And Monkeys

Subretinal Delivery Of Eiav-based Lentiviral Vectors In The Shaker1 Mouse Model For Usher Syndrometype 1b : Development Of Ushstat®

To View More...

You must be signed into an individual account to use this feature.